GILD News 108.71 09/25/2014 05:00:43 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 108.71 $GILD

'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - 1 hr ago
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.

Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.

Gilead reports good HIV trial
at Investor's Business Daily - Wed Sep 24, 5:30PM CDT
The biotech reported good late-stage trial data for its new HIV drug. The trial compared a standard combination of drugs in Gilead's (GILD) Stribild to a trial in which 1 of the components, sold individually as Viread, was replaced with tenofovir...

Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.

Final Glance: Biotechnology companies
AP - Wed Sep 24, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:00PM CDT
Gilead (GILD) is seeking Japanese approval for the combination of Sovaldi and ledipasvir .

Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.

Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:20PM CDT
Emergent BioSolutions (EBS) initiated a pivotal non-clinical study on BioThrax to support the licensure of the company's new modern facility, Building 55.

Watch for Gilead Sciences to Potentially Pullback After Gaining 3.10% Yesterday
Comtex SmarTrend(R) - Wed Sep 24, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $106.02 to a high of $108.81. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $107.89 on volume of 14.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 3.10% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 24, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $106.02 to a high of $108.81. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $107.89 on volume of 14.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Gilead's Next-Gen HIV Drug Bests Stribild In Trials
at Investor's Business Daily - Wed Sep 24, 12:39PM CDT
Big-cap biotech and IBD 50 stock Gilead Sciences (GILD) reported good late-stage trial data for its new HIV drug Wednesday. Analysts nicknamed the drug "son of Viread" and expect it to be a blockbuster. The stock was up about 2.2% by afternoon...

Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...

Midday Glance: Biotechnology companies
AP - Wed Sep 24, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Early Glance: Biotechnology companies
AP - Wed Sep 24, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver
PR Newswire - Wed Sep 24, 9:33AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, AMBA, AGNC, NTAP and F.

Gilead Sciences' Next-Generation HIV Drug Hits the Mark
at The Street - Wed Sep 24, 9:30AM CDT
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.

Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 8:39AM CDT
Acceleron Pharma (XLRN) was a big mover last session, as its shares rose almost 13% on the day.

Sangamo Biosciences (SGMO) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 7:51AM CDT
Sangamo Biosciences Inc. (SGMO) was a big mover last session, as its shares rose over 5% on the day.

The Next Blue Chip Stocks: Gilead Sciences, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Sep 24, 7:35AM CDT
Source: Gilead Sciences via Google Maps Great blue chip stocks aren't made overnight and they're rarely content playing second fiddle in their market. Instead, they're established leaders that dominate their competition. By that definition,...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 76

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
DPR’s Parent Benefits Signal a Tougher Labor Market

Updated Category News Views 34

Concrete Schedules Do Not Bend Easily A jobsite does not care that daycare closes at 6 p.m., and that is exactly why DPR Construction’s latest workplace recognition deserves a closer look. The privately held, employee-owned contractor landed at No. 29 among large companies on the 2026 Fortune Best Workplaces for Parents list. It is not a quarterly earnings event, and...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 87

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 16

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Chipotle's Thanksgiving BOGO Tests Loyalty Muscle Again

Updated Category News Views 35

Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Westpac's CEO Calls for Enhanced Social Media Fraud Measures

Updated Category News Views 140

Westpac's Urgent Plea for Enhanced Fraud Prevention Westpac Banking Corp's CEO has made a significant call for social media companies, including Meta Platforms, to take a more proactive role in fighting online financial fraud. With an alarming rise in scams targeting consumers, this appeal highlights the urgent need for a united front against fraudulent activities online....

Continue Reading
Empowering Veterans: Bombardier's Commitment to Career Success

Updated Category News Views 170

Empowering Veterans Through Partnership with the Army Today, Bombardier proudly announces its partnership with the U.S. Army via the Partnership for Your Success (PaYS) Program. This initiative is designed to connect service members with valuable civilian career opportunities, ensuring they receive guaranteed job interviews with participating employers. This strategic...

Continue Reading
AWH Faces Market Challenges with Stock at Record Low

Updated Category News Views 107

AWH Stock Experiences Significant Decline AWH stock has recently dropped to a concerning 52-week low of $0.38, reflecting the tough market conditions. The dip in stock price highlights the company’s struggles, with its market capitalization now at a mere $6.5 million. Over the past year, the stock has lost approximately 90.68% of its value, showcasing a substantial...

Continue Reading
Vimeo's Q3 2024 Financial Insights and Future Outlook

Updated Category News Views 370

Vimeo Posts Third Quarter 2024 Financial Update Vimeo recently shared its financial snapshot for the third quarter of 2024, showcasing the company's growth trajectory and key achievements. The shareholder letter is now available on the investor relations section of their website, allowing stakeholders to delve into the details. This transparency is vital for maintaining...

Continue Reading
Implantica's Year-End Report Highlights RefluxStop Progress

Updated Category News Views 165

Implantica's Year-End Report: Driving Forward with Innovation Implantica has made significant strides in the healthcare sector, particularly with its innovative product, RefluxStop™, which aims to transform how gastroesophageal reflux is treated. This year-end report presents a comprehensive overview of the company's achievements for the year. RefluxStop™ FDA...

Continue Reading